 |
|
Many receptor models used in drug design may not be useful after all
October 03, 2008Architectural code of caffeine's main target in the body finally cracked
Many receptor models used in drug design may not be useful after all
It may very well be that models used for the design of new drugs have to be regarded as impractical. This is the sobering though important conclusion of the work of two Leiden University scientists published in Science this week. The editorial board of the renowned journal even decided to accelerate the publication on the crystal structure of the adenosine A2A receptor via Science Express. Together with an expert team at the Scripps Institute (La Jolla) led by crystallographer Ray Stevens, Ad IJzerman, head of the division of medicinal chemistry at the Leiden/Amsterdam Center for Drug Research, and postdoctoral fellow Rob Lane worked on the structure elucidation of this protein, which is one of caffeine's main targets in the human body, and a key player in Parkinson's disease.
Fatty
Obtaining a crystal structure of a receptor bound to a drug is by far the best way to learn and appreciate how drugs actually work. "For decades scientists from all over the world have struggled to get the crystal structure of this type of G protein-coupled receptor", IJzerman explains. "These arduous attempts are easily understood when one takes into account that the whole family of these proteins are the targets for almost half of the medicines that are available in the pharmacy shop. It seemed an impossible task, since these proteins are in the cell wall, which means they are in a fatty environment, and are fatty themselves. We all know that fat does not crystallize easily."
Fusion product
The scientists in California had found an elegant solution for this problem though. They coupled the receptor protein to another protein that, in contrast, crystallizes easily, and managed to obtain tiny crystals of the fusion product. That was sufficient to crack the architectural code of the protein, for which very advanced crystallization equipment was used. In fact, something similar had worked for yet another receptor, but this time it was an adenosine receptor's turn. These receptors are at the core of the research in the division of medicinal chemistry of the Leiden/Amsterdam Center for Drug Research, and that's exactly why the American colleagues turned to the Leiden group. Forces were joined, and that's how the receptor constructs were characterized biochemically and pharmacologically, while at the same time the crystallization trials were ongoing across the Atlantic.
Supercaffeine
By the end of June 2008 the first crystals of suitable quality had been obtained and analyzed. That led to a big surprise that will undoubtedly have tremendous implications for the pharmaceutical industry. "The binding site for drugs on this receptor is very different from the one that had been found on two other receptors that we currently know the crystal structure of", says Rob Lane, asked for comments. "In the adenosine A2A receptor a small molecule, prosaically called ZM241385, is co-crystallized. This compound has high affinity for the receptor, and therefore it is best described as some sort of 'supercaffeine', a type of molecule that we had worked on in Leiden before." With some degree of understatement, Lane continues: "The drug is in a very different position than was expected on the basis of the other crystal structures. And there's the rub; almost everybody in the world of drug design has so far used receptor models that may not be so useful at all. That is the sobering and at the same time important discovery we made."
Leiden University
Fatty
Obtaining a crystal structure of a receptor bound to a drug is by far the best way to learn and appreciate how drugs actually work. "For decades scientists from all over the world have struggled to get the crystal structure of this type of G protein-coupled receptor", IJzerman explains. "These arduous attempts are easily understood when one takes into account that the whole family of these proteins are the targets for almost half of the medicines that are available in the pharmacy shop. It seemed an impossible task, since these proteins are in the cell wall, which means they are in a fatty environment, and are fatty themselves. We all know that fat does not crystallize easily."
Fusion product
The scientists in California had found an elegant solution for this problem though. They coupled the receptor protein to another protein that, in contrast, crystallizes easily, and managed to obtain tiny crystals of the fusion product. That was sufficient to crack the architectural code of the protein, for which very advanced crystallization equipment was used. In fact, something similar had worked for yet another receptor, but this time it was an adenosine receptor's turn. These receptors are at the core of the research in the division of medicinal chemistry of the Leiden/Amsterdam Center for Drug Research, and that's exactly why the American colleagues turned to the Leiden group. Forces were joined, and that's how the receptor constructs were characterized biochemically and pharmacologically, while at the same time the crystallization trials were ongoing across the Atlantic.
Supercaffeine
By the end of June 2008 the first crystals of suitable quality had been obtained and analyzed. That led to a big surprise that will undoubtedly have tremendous implications for the pharmaceutical industry. "The binding site for drugs on this receptor is very different from the one that had been found on two other receptors that we currently know the crystal structure of", says Rob Lane, asked for comments. "In the adenosine A2A receptor a small molecule, prosaically called ZM241385, is co-crystallized. This compound has high affinity for the receptor, and therefore it is best described as some sort of 'supercaffeine', a type of molecule that we had worked on in Leiden before." With some degree of understatement, Lane continues: "The drug is in a very different position than was expected on the basis of the other crystal structures. And there's the rub; almost everybody in the world of drug design has so far used receptor models that may not be so useful at all. That is the sobering and at the same time important discovery we made."
Leiden University
Drug Design Current Events and Drug Design News RSSScientists Present 'Moving' Theory Behind Bacterial Decision-Making
Biochemists at North Carolina State University have answered a fundamental question of how important bacterial proteins make life-and-death decisions that allow them to function, a finding that could provide a new target for drugs to disrupt bacterial decision-making processes and related diseases.
Quantum computers could excel in modeling chemical reactions
Quantum computers would likely outperform conventional computers in simulating chemical reactions involving more than four atoms, according to scientists at Harvard University, the Massachusetts Institute of Technology, and Haverford College.
NYU scientists identify critical protein complex in formation of cell cilia
An international team led by NYU Cancer Institute have identified a protein complex that regulates the formation of cilia, which are found on virtually all mature human cells and are essential to normal cell function.
NYU researchers demonstrate activity of mebendazole in metastatic melanoma
Researchers at the NYU Cancer Institute and the Ronald O. Perelman Department of Dermatology have identified mebendazole, a drug used globally to treat parasitic infections, as a novel investigational agent for the treatment of chemotherapy-resistant malignant melanoma.
UCLA researchers clarify function of glucose transport molecule
Researchers at the David Geffen School of Medicine at UCLA have solved the structure of a class of proteins known as sodium glucose co-transporters (SGLTs), which pump glucose into cells.
Spit tests may soon replace many blood tests
One day soon patients may spit in a cup, instead of bracing for a needle prick, when being tested for cancer, heart disease or diabetes. A major step in that direction is the cataloguing of the "complete" salivary proteome, a set of proteins in human ductal saliva, identified by a consortium of three research teams.
Toward the ethical treatment of whole genome research participants
Recent technological developments have made it possible for scientists to sequence an entire human genome, but these advances may be a mixed blessing.
CSHL scientists discover new details of a gene-regulatory network governing metabolism
Metabolism is a central feature of life - a myriad of biochemical processes that, together, enable organisms to nourish and sustain themselves. Scientists at Cold Spring Harbor Laboratory (CSHL) are in the forefront of efforts to demonstrate how the regulation of genes governs fundamental life processes, including metabolism.
Researchers discover new way to reverse poor circulation and heal wounds
Researchers have solved a longstanding mystery about how flexing muscles "tell" nearby blood vessels that they need more blood to perform, according to a study published Feb. 15 in the journal Circulation Research.
Genetic differences may help explain response to multiple sclerosis treatment
By comparing the DNA of patients with multiple sclerosis whose symptoms are reduced by interferon beta therapy to the DNA of those who continue to experience relapses, researchers may have identified important genetic differences between the two.
More Drug Design Current Events and Drug Design News Articles
 | The Organic Chemistry of Drug Design and Drug Action, Second Edition by Richard B. Silverman Standard medicinal chemistry courses and texts are organized by classes of drugs with an emphasis on descriptions of their biological and pharmacological effects. This book represents a new approach based on physical organic chemical principles and reaction mechanisms that rationalized drug action and allowed the reader to extrapolate to many related classes of drug molecules. The second edition... |
| Textbook of Drug Design and Discovery, Fourth Edition by Ulf Madsen, Povl Krogsgaard-Larsen, Kristian Stromgaard Updated and revised, this fourth edition of a perennial bestseller provides current and comprehensive information on all aspects of drug design and discovery. It describes specific strategies employed by medicinal chemists to advance promising molecules into clinical use for the alleviation of disease. The fourth edition includes new chapters on products of natural origin as leads in drug design,... | |
 | Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization by Edward Kerns, Li Di Of the thousands of novel compounds that a drug discovery project team invents and that bind to the therapeutic target, typically only a fraction of these have sufficient ADME/Tox properties to become a drug product. Understanding ADME/Tox is critical for all drug researchers, owing to its increasing importance in advancing high quality candidates to clinical studies and the processes of drug... |
 | The Organic Chemistry of Drug Design and Drug Action, Power PDF, Second Edition by Richard B. Silverman This CD-ROM edition of Silverman's Organic Chemisry of Drug Design and Drug Action, Second Edition reflects the significant changes in the drug industry in recent years, using an accessible interactive approach. This CD-ROM integrates the author's own PowerPoint slides, indexed and linked to the book pages in PDF format. The three-part structure includes an all-electronic text with full-text... |
 | Textbook of Drug Design and Discovery, Third Edition Building on the success of the second edition, Textbook of Drug Design has been thoroughly revised and updated to provide a complete source of information on all facets of drug design for students of chemistry, pharmacy, pharmacology, biochemistry and medicine. The book follows drug design from the initial structure-activity relationship to the final processes of clinical evaluation and... |
 | Cancer Drug Design and Discovery The ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumours. Unique sections... |
 | Drug Metabolism in Drug Design and Development The essentials of drug metabolism vital to developing new therapeutic entities. Information on the metabolism and disposition of candidate drugs is a critical part of all aspects of the drug discovery and development process. Drug metabolism, as practiced in the pharmaceutical industry today, is a complex, multidisciplinary field that requires knowledge of sophisticated analytical technologies... |
 | Fragment-based Approaches in Drug Discovery (Methods and Principles in Medicinal Chemistry) This first systematic summary of the impact of fragment-based approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this represents a book by professionals for professionals, tailor-made for drug developers in the pharma and biotech sector who need to keep up-to-date on the latest technologies and... |
 | Drug Discovery and Development, Drug Discovery (Volume 1) This two volume set provides a comprehensive account of the entire sequence of operations involved in discovering a drug through the actual delivery of the drug to clinicians and medical practitioners. Includes case studies of the discovery of erythromycin analogs (antibiotics), Tagamet, and Ultiva (remifentanil) Discusses the discovery of agents for the treatment and management... |
 | Pharmacokinetics in Drug Development: Clinical Study Design and Analysis (Volume 1) (Biotechnology: Pharmaceutical Aspects) (v. 1) These volumes are designed to be the most complete guide to pharmacokinetics (PK) and its role in drug development. Geared toward graduate level students and scientists in the areas of clinical pharmacology and PK, the volumes will fill a gap between the academic science and the practical application of that knowledge in drug development. Volume 1 discusses the role that PK plays in selected... |
| © 2009 BrightSurf.com |